Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 107,922,056
  • Shares Outstanding, K 1,305,930
  • Annual Sales, $ 30,390 M
  • Annual Income, $ 13,501 M
  • 36-Month Beta 1.19
  • Price/Sales 3.54
  • Price/Cash Flow 6.53
  • Price/Book 4.65

Price Performance

See More
Period Period Low Period High Performance
1-Month
72.08 +14.65%
on 08/21/17
86.27 -4.21%
on 09/08/17
+10.53 (+14.60%)
since 08/18/17
3-Month
65.61 +25.96%
on 06/21/17
86.27 -4.21%
on 09/08/17
+17.05 (+25.99%)
since 06/20/17
52-Week
63.76 +29.61%
on 06/16/17
86.27 -4.21%
on 09/08/17
+0.86 (+1.05%)
since 09/20/16

Most Recent Stories

More News
Gilead Receives Approval in Canada for Expanded Indication of EPCLUSA® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV

- New Data for First Approved Pan-genotypic Once-Daily Single Tablet Regimen for Chronic Hepatitis C Virus Infection -

GILD : 82.64 (+0.43%)
Ohio's Yes on Issue 2: U.S. Consumers Pay $84,000 for a Drug Egyptians Buy for $83!!

Sovaldi, the hepatitis C wonder drug, sells for $84,000 in the U.S. but for only $83 in Egypt, says the British tabloid the Daily Mail. The newspaper also reports Egyptian entrepreneurs are...

GILD : 82.64 (+0.43%)
Should Value Investors Consider Gilead Sciences (GILD) Stock?

Gilead Sciences (GILD) appears to be a good choice for value investors right now, given its favorable metrics and estimate revisions.

GILD : 82.64 (+0.43%)
Gilead Prices $3 Billion of Senior Unsecured Notes

Gilead Sciences, Inc. (NASDAQ:GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $3 billion, in an underwritten, registered public offering, consisting...

GILD : 82.64 (+0.43%)
4 Biotech Stocks That Show Promise on Sustainable Growth

Biotech sector is performing well in 2017 due to an increase in FDA approvals, new product sales ramp up, R&D success and innovation, strong clinical study results and continued strong performance of legacy...

SGMO : 14.35 (-0.69%)
HSKA : 88.87 (+0.65%)
CORT : 17.88 (-0.56%)
LLY : 82.02 (+0.35%)
HLUYY : 58.8300 (+1.19%)
GILD : 82.64 (+0.43%)
KITE : 179.74 (+0.13%)
ALXN : 142.92 (+0.06%)
Options Traders Expect Huge Moves in Gilead Sciences (GILD) Stock

Gilead Sciences (GILD) needs Investors to pay close attention to the stock based on moves in the options market lately.

GILD : 82.64 (+0.43%)
3 Pharma/Biotech Sector Bargains for a Healthy Portfolio

The biotech sector has turned around after its dismal performance in 2016 as uncertainty surrounding drug pricing control subsides. A few stocks are however still undervalued, which may gain going ahead....

PDLI : 3.31 (+0.61%)
JAZZ : 148.07 (-2.06%)
GRFS : 20.79 (+0.05%)
GILD : 82.64 (+0.43%)
KITE : 179.74 (+0.13%)
Should You Keep Your Portfolio Healthy with Biotech ETFs?

Biotech ETFs are riding high on research and developments and FDA approvals.

BBC : 28.92 (+0.84%)
CNCR : 26.36 (-1.09%)
IBB : 332.75 (+0.85%)
VRTX : 152.72 (-0.18%)
BBH : 134.10 (+0.67%)
LABU : 81.41 (+5.19%)
K : 64.72 (-1.75%)
BBP : 40.94 (+0.12%)
SBIO : 31.42 (+0.77%)
UBIO : 38.43 (+2.62%)
CLVS : 75.04 (-1.28%)
BIB : 60.91 (+1.60%)
GILD : 82.64 (+0.43%)
SPY : 250.06 (+0.04%)
XBI : 85.17 (+1.77%)
Should You Keep Your Portfolio Healthy with Biotech ETFs?

Biotech ETFs are riding high on research and developments and FDA approvals.

BBC : 28.92 (+0.84%)
CNCR : 26.36 (-1.09%)
IBB : 332.75 (+0.85%)
VRTX : 152.72 (-0.18%)
BBH : 134.10 (+0.67%)
LABU : 81.41 (+5.19%)
K : 64.72 (-1.75%)
BBP : 40.94 (+0.12%)
SBIO : 31.42 (+0.77%)
UBIO : 38.43 (+2.62%)
CLVS : 75.04 (-1.28%)
BIB : 60.91 (+1.60%)
GILD : 82.64 (+0.43%)
SPY : 250.06 (+0.04%)
XBI : 85.17 (+1.77%)
Companies to Watch as Biotech Makes a Comeback in 2017

This is a bull market, and some biotech stocks are the real raging bulls-especially when massive drug pipelines are at stake, and landmark FDA approvals shake things up with massive share price momentum....

CELG : 144.24 (+0.54%)
NVS : 85.78 (-0.08%)
GILD : 82.64 (+0.43%)
CALA : 16.45 (+2.17%)
KITE : 179.74 (+0.13%)
REGN : 438.17 (+1.57%)
CELGZ : 1.25 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections...

See More

Support & Resistance

2nd Resistance Point 83.52
1st Resistance Point 83.08
Last Price 82.64
1st Support Level 82.02
2nd Support Level 81.40

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.